The new site, the contract development and manufacturing organization (CDMO) said, will be the largest end-to-end cell culture manufacturing facility in North America and will feature two large manufacturing suites for drug substance m anufacturing, packaging, assembly and labeling.

Once completed, the new facility will serve large-scale clients across Europe and the United States and also create 725 manufacturing jobs in North Carolina by the end of 2028. Janssen Supply Group, a subsidiary of Johnson & Johnson company, will be the first tenant and has committed to one of the production suites, said Fujifilm.

Lars Petersen, president and CEO of Fujifilm Diosynth Biotechnologies, said: “In addition to being a valued partner to our customers, Fujifilm Diosynth Biotechnologies is also a partner for the planet. I am incredibly proud of our team for implementing innovative sustainability features in the facility design including preservation of water, wetlands, and biodiversity, as well as diverting waste from landfills. We are delivering on our commitment to build this facility with sustainability at its core, as well as our commitment to Fujifilm’s Sustainable Value Plan 2030, and I look forward to celebrating our achievement of certification of LEED gold standards for the site.”